aod9604 peptide weight loss evidence clinical trials META TITLE 6mg Research aod9604 clinical trial weight loss

This guide summarizes our core findings on GHK-Cu peptide research, before-and-after timelines, dosage considerations, and real-world user experiences

7-1515, Apr

In naturally aged mouse models (1820 months old), daily oral administration of 5-amino-1mq capsules for 12 consecutive weeks significantly reduced NNMT activity and increased NAD+ levels in various tissues (liver, kidney, adipose tissue), along with markedly elevated expression of SIRT1 and SIRT3 proteins

Cox, Daniel Eichner Published: Drug Testing and Analysis, Volume 7, Issue 1, January 2015, pages 3138 DOI: 10.1002/dta.1715 URL: AOD9604 was incubated in human serum and rat plasma at room temperature to study in vitro metabolic degradation